目的：研究探讨瑞替普酶和尿激酶静脉溶栓对于急性心肌梗死患者并发症发生情况的影响。方法100例急性心肌梗死患者，随机为常规组和实验组，各50例。常规组使用尿激酶进行静脉溶栓治疗，实验组使用瑞替普酶进行静脉溶栓治疗，对比两组的并发症发生情况、急性期的病死率以及溶栓治疗2 h 内冠状动脉的再通率。结果实验组患者2 h 内的再通率84%高于常规组66%，差异具有统计学意义(P<0.05)。实验组患者的并发症发生率16%低于常规组34%，差异具有统计学意义(P<0.05)。实验组患者急性期的病死率6%低于常规组20%，差异具有统计学意义(P<0.05)。结论在急性心肌梗死的治疗中，瑞替普酶的疗效要优于尿激酶，值得在临床上进行推广。%Objective To study and explore effect of reteplase and urokinase intravenous thrombolysis on occurrence of complications in acute myocardial infarction patients. Methods A total of 100 acute myocardial infarction patients were randomly divided into conventional group and experimental group, with 50 cases in each group. The conventional group received urokinase for intravenous thrombolysis treatment, and the experimental group received reteplase for intravenous thrombolysis treatment. Comparison were made on incidence of complications, fatality rate in acute stage and recanalization rate of coronary artery in 2 h of thrombolytic therapy in two groups. Results The experimental group had higher recanalization rate in 2 h as 84% than 66% in the conventional group, and the difference had statistical significance (P<0.05). The experimental group had lower incidence of complications as 16% than 34% in the conventional group, and the difference had statistical significance (P<0.05). The experimental group had lower fatality rate in acute phase as 6% than 20% in the conventional group, and the difference had statistical significance (P<0.05). Conclusion Reteplase provides higher curative effect for the treatment of acute myocardial infarction than urokinase, and it is worth promotion in clinical.
展开▼
